Monday, 19 January 2015

CRC Regimens Give Survival Bump in Second Line

(MedPage Today) -- Ramucirumab trial meets primary endpoint; famitinib offers respectable disease control rate. via MedPageToday.com - medical news plus CME for physicians Read More Here..
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)